INVA Innoviva Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: INVA

Price (delayed)

$20.24

Market cap

$1.46B

P/E Ratio

4.01

Dividend/share

N/A

EPS

$5.05

Enterprise value

$1.15B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 99

Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic ...

Highlights
The stock's price to earnings (P/E) is 60% less than its 5-year quarterly average of 10.4 and 26% less than its last 4 quarters average of 5.6
The debt has contracted by 42% YoY
The equity has surged by 73% year-on-year but it has declined by 8% since the previous quarter
The company's EPS fell by 30% QoQ
INVA's net income is down by 29% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.inva.com
Peers: OPK ORGO

Key stats

What are the main financial stats of INVA

INVA stock price

How has the Innoviva stock price performed over time
Intraday
-3.53%
1 week
-4.53%
1 month
-3.94%
1 year
5.97%
YTD
1.25%
QTD
-10.88%

Financial performance

How have Innoviva's revenue and profit performed over time
Revenue
$440M
Gross profit
$317.66M
Operating income
$162.58M
Net income
$357.24M
Gross margin
72.2%
Net margin
81.2%
The net margin has contracted by 32% from the previous quarter
INVA's net income is down by 29% since the previous quarter
The operating margin has decreased by 23% YoY and by 3.1% from the previous quarter
The revenue has grown by 19% YoY and by 4.6% from the previous quarter

Price vs fundamentals

How does INVA's price correlate with its fundamentals

Growth

What is Innoviva's growth rate over time

Valuation

What is Innoviva stock price valuation
INVA P/E details
P/E
4.01
P/B
1.21
P/S
3.38
EV/EBIT
2.63
EV/EBITDA
2.41
EV/Sales
2.61
The stock's price to earnings (P/E) is 60% less than its 5-year quarterly average of 10.4 and 26% less than its last 4 quarters average of 5.6
The company's EPS fell by 30% QoQ
The equity has surged by 73% year-on-year but it has declined by 8% since the previous quarter
The P/B is 30% below the 5-year quarterly average of 1.8 and 3.1% below the last 4 quarters average of 1.3
The revenue has grown by 19% YoY and by 4.6% from the previous quarter
The P/S is 13% higher than the 5-year quarterly average of 3.1 but 2.8% lower than the last 4 quarters average of 3.6

Efficiency

How efficient is Innoviva business performance
INVA's return on equity is down by 37% since the previous quarter
INVA's ROA is down by 33% from the previous quarter
The return on invested capital has declined by 33% since the previous quarter
The company's return on sales fell by 32% QoQ

Dividends

What is INVA's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history

Special dividends are included in TTM DPS and yield

Financial health

How did Innoviva financials performed over time
The total assets rose by 28% year-on-year but it has declined by 7% since the previous quarter
The total liabilities has decreased by 24% YoY and by 5% from the previous quarter
The debt is 79% less than the equity
The equity has surged by 73% year-on-year but it has declined by 8% since the previous quarter
The debt to equity has dropped by 67% year-on-year but it has grown by 11% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.